Journal of Clinical Endocrinology & Metabolism, Vol 76, 151-155, Copyright © 1993 by Endocrine Society

ARTICLES

Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin

L Laue, J Jones, KM Barnes and GB Cutler Jr
Development Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.

Combined antiandrogen (spironolactone) and aromatase inhibitor (testolactone) are effective for the short term treatment of familial male precocious puberty. During this therapy, plasma testosterone levels remain in the adult range, since spironolactone blocks the testosterone receptor without significantly affecting plasma testosterone levels. After our initial 18-month pilot study, we continued to treat eight boys with the combined therapy for 2.0-4.2 yr. During this time all boys exhibited a pubertal rise in gonadotropin secretion and a diminishing response to treatment, which was manifested by the recurrence of clinical features of puberty and an increase in the bone maturation rate (P < 0.05). Addition of the LHRH agonist deslorelin (4 micrograms/kg.day, sc) to the combined therapy decreased peak LH, plasma testosterone, bone maturation rate, and growth velocity (P < 0.05) over the next year. We conclude that the rise in gonadotropin levels during central activation of hypothalamic LHRH secretion in boys with familial male precocious puberty causes a partial escape from the combined effect of spironolactone and testolactone. The addition of deslorelin to the combined therapy appears to restore the control of puberty in this setting.

This article has been cited by other articles:

				D. I. Shulman, G. L. Francis, M. R. Palmert, E. A. Eugster, and for the Lawson Wilkins Pediatric Endocrine Society Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development Pediatrics, April 1, 2008; 121(4): e975 - e983. [Abstract] [Full Text] [PDF]

				L. Soriano-Guillen, N. Lahlou, G. Chauvet, M. Roger, J. L. Chaussain, and J. C. Carel Adult Height after Ketoconazole Treatment in Patients with Familial Male-Limited Precocious Puberty J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 147 - 151. [Abstract] [Full Text] [PDF]

				J.-C. Carel, N. Lahlou, M. Roger, and J. L. Chaussain Precocious puberty and statural growth Hum. Reprod. Update, March 1, 2004; 10(2): 135 - 147. [Abstract] [Full Text] [PDF]

				E. W. Leschek, J. Jones, K. M. Barnes, S. C. Hill, and G. B. Cutler Jr. Six-Year Results of Spironolactone and Testolactone Treatment of Familial Male-Limited Precocious Puberty with Addition of Deslorelin after Central Puberty Onset J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 175 - 178. [Abstract] [Full Text]

				E. A. Cummings, S. R. Salisbury, M. L. Givner, and R. S. Rittmaster Testolactone-Associated High Androgen Levels, a Pharmacologic Effect or a Laboratory Artifact? J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 784 - 787. [Abstract] [Full Text]

				J. Gromoll, C.-J. Partsch, M. Simoni, V. Nordhoff, W. G. Sippell, E. Nieschlag, and B. B. Saxena A Mutation in the First Transmembrane Domain of the Lutropin Receptor Causes Male Precocious Puberty J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 476 - 480. [Abstract] [Full Text]